Wichtige Information des Bundesamtes für Sicherheit im Gesundheitswesen über das Auftreten von schwerwiegenden Nebenwirkungen zu Velactis Schwerwiegende Nebenwirkungen sind kurz nach Markteinführung von Velactis im März 2016 gemeldet worden. Die gemeldeten Symptome sind Festliegen, Hypothermie, Hypokalzämie, Funktionsstörung des Pansens,…

The marketing authorization holder informed its supplied customers in a letter dated June 20, 2016, that a precautionary recall is being carried out due to the potential risk of glass particles in the vials.

For detailed information, please contact us and EMA .

The marketing authorization holder has informed its supplied customers in a letter dated 09.05.2016 that due to a technical error during production, there are residues of corrosive agents in the dry substance. Therefore, the two above mentioned batches of "Rifoldin 600mg dry substance for infusion preparation with solvent" are recalled as a…

Please note the changed BIC for transfers to the accounts of the Federal Office for Safety in Health Care (BASG) / AGES Medizinmarktaufsicht. (The IBAN numbers do not change). Account details for fee advances: BAWAG P.S.K. AG IBAN: AT59 6000 0000 9605 1496 BIC: BAWAATWW Account data for the medical device fee: BAWAG P.S.K. BankIBAN: AT84…

The marketing authorization holder has informed its supplied customers by letter dated April 20, 2016, that an internal quality control has detected an undercutting of the phenol content and therefore the affected batches of the Prick Test Solution Pineapple will be recalled.

The marketing authorization holder informed its supplied customers in a letter dated 19.04.2016 that an error in the filling process was detected at the manufacturer. The error results in a few vials possibly containing a too high concentration. The too high concentration results from the partial evaporation of the solvent ethanol, but the total…

The marketing authorization holder has informed its supplied customers in a letter dated 20.04.2016 that the marketing authorizations of medicinal products containing fusafungin (Locabiosol / Bioparox / Locabiotal / Fusaloyos as oral spray, nasal spray or as solution) will be revoked within the EU.These medicines are used for the treatment of upper…

The marketing authorization holder has informed its supplied customers in a letter dated April 15, 2016, that a possible non-sterility cannot be excluded and therefore a precautionary recall is being carried out. This recall results from an inspection by the Spanish surveillance authority (AEMPS) at the manufacturer Inmunotek S. L., during which it…

In a letter dated April 13, 2016, the marketing authorization holder informed its customers that the above-mentioned batch of "Curatoderm - Ointment" was found to be mixed with "Amciderm - Cream" and is therefore being recalled. "Amciderm - Creme" is not approved in Austria.